Patients were randomly assigned to receive either subcutaneous denosumab 120 mg and intravenous placebo (n = 1,026) or intravenous zoledronic acid 4 mg adjusted for creatinine clearance and ...

There were similar increases in bone mineral density in all the zoledronic acid groups to values for the spine that were 4.3 to 5.1 percent higher than those in the placebo group (P<0.001 ...

A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual ...

June 1, 2008 (updated June 4, 2008) (Chicago, Illinois) — zoledronic acid, a bisphosphonate used for bone metastases and osteoporosis, has shown a significant benefit in early breast cancer in ...

As with all medications, the cost of zoledronic acid can vary. Factors that may affect the price you’ll pay include your treatment plan and your insurance coverage. It may also depend on the ...

Adults with osteoporosis prescribed zoledronic acid have an increased risk for atrial fibrillation when compared with denosumab, according to a study data. Sara Jane Cromer “While previous ...

Comparison of Diameter and Perimeter Methods for Tumor Volume Calculation PURPOSE: Two identical, concurrent, parallel, multicenter, randomized, double-blind, double-dummy trials were conducted to ...

The use of upfront bisphosphonates has been tested in 3 large trials of zoledronic acid in women with early breast cancer receiving the AI letrozole. All 3 of these studies — Z-FAST, ZO-FAST ...

In our study, a single dose of zoledronic acid given 24 to 35 weeks after the last dose of denosumab was effective at maintaining the large and rapid gains in spine and hip bone mineral density ...

What Regional Insights Are Provided In The Report? North America was the largest region in the zoledronic acid market in 2024, with other regions covered in the report including the Asia-Pacific, ...